Coleman and Slomovitz Continue the Discussion on Maintenance PARP Inhibition in Ovarian Cancer

Season 3 Episode 35  ·  Sep 03, 2020, 06:45 PM
Headliner
Share
Subscribe

In our exclusive interview, Dr. Coleman and Dr. Slomovitz discussed the benefits and limitations of PARP inhibition in all-comers with newly diagnosed advanced ovarian cancer and pivotal PARP inhibitor trials in the frontline setting.

Share
Subscribe
Next
Herzog and Moore Mull Over the Role of Maintenance PARP Inhibition in Ovarian Cancer
Top episodes
DeNunzio Describes the Advantages of Proton Beam Therapy in Oncology
by OncLive® On Air
FDA Approval Insights: Amivantamab and Mobocertinib in EGFR Exon 20 Insertion+ NSCLC
by OncLive® On Air
Milhem Talks Mechanism of Action, Delivery Methodology, and Ongoing Trials With RP1
by OncLive® On Air